Neuromedin U-25 (human)
目录号 : GC44379
Neuromedin U-25 (human)是一种由25个氨基酸组成的内源性肽,具有强效的平滑肌收缩活性。
Cas No.:312306-89-1
Sample solution is provided at 25 µL, 10mM.
Neuromedin U-25 (human) is a 25-amino-acid endogenous peptide with potent smooth muscle contractile activity [1]. Neuromedin U-25 can bind to the conserved binding pocket of two subtypes of the Neuromedin U receptors, thereby activating Gq/11[2]. Neuromedin U-25 has been widely used in the regulation of appetite and the control of energy balance[3].
In vitro, Neuromedin U-25 treatment for 4 hours significantly increased the mRNA levels of IL-5 and IL-13 in Th2 cells, with EC50 values of 3.5nM and 4.5nM respectively[4].
References:
[1] Mitchell J D, Maguire J J, Kuc R E, et al. Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system[J]. Cardiovascular research, 2009, 81(2): 353-361.
[2] You C, Zhang Y, Xu P, et al. Structural insights into the peptide selectivity and activation of human neuromedin U receptors[J]. Nature Communications, 2022, 13(1): 2045.
[3] Martinez V G, O'Driscoll L. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles[J]. Clinical chemistry, 2015, 61(3): 471-482.
[4] Ye Y, Luo J, Zeng N, et al. Neuromedin U promotes human type 2 immune responses[J]. Mucosal Immunology, 2022, 15(5): 990-999.
Neuromedin U-25 (human)是一种由25个氨基酸组成的内源性肽,具有强效的平滑肌收缩活性[1]。Neuromedin U-25能结合至神经调节肽U受体的两个亚型的保守结合口袋,从而激活Gq/11蛋白[2]。Neuromedin U-25已广泛应用于食欲调节与能量平衡控制[3]。
在体外,使用Neuromedin U-25处理Th2细胞4小时,可显著提高IL-5和IL-13的mRNA水平,EC50值分别为3.5nM和4.5nM[4]。
| Cell experiment [1]: | |
Cell lines | Th2 cells |
Preparation Method | Th2 cells grow in RPMI medium containing 10% human serum, 1×L-glutamine, 1×penicillin/streptomycin, 1×pyruvate sodium, 1×MEM NEAA, 10mM HEPES buffer, 50µM 2-mercaptoethanol and 250U/ml IL-2. After being treated with different concentrations of Neuromedin U-25 (0.001, 0.01, 0.1, 1, and 10nM) for 4 hours, the concentrations of IL-5 and IL-13 in the cell were detected. |
Reaction Conditions | 0.001, 0.01, 0.1, 1, and 10nM; 4h |
Applications | Neuromedin U-25 treatment significantly enhanced the concentrations of IL-5 and IL-13 in Th2 cells in a dose-dependent manner. |
References: | |
| Cas No. | 312306-89-1 | SDF | |
| Canonical SMILES | NC([C@H](CC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@@H]1CCCN1C([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H](CC(C)C)NC([C@@H](NC([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@H](CO)NC([C@@H](NC([C@@H](NC([C@@H]2CCCN2C([C@H](CO)NC([C@H](CCC(N)=O)NC( | ||
| 分子式 | C141H203N41O38 | 分子量 | 3080.4 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 324.6 μL | 1.6232 mL | 3.2463 mL |
| 5 mM | 64.9 μL | 324.6 μL | 649.3 μL |
| 10 mM | 32.5 μL | 162.3 μL | 324.6 μL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















